Related references
Note: Only part of the references are listed.A randomized evaluation of vinorelbine versus gemcitabine chemotherapy mobilization of stem cells in myeloma patients
Barbara Jeker et al.
BONE MARROW TRANSPLANTATION (2020)
Reduced survival after autologous stem cell transplantation in myeloma and lymphoma patients with low vitamin D serum levels
Florian Eicher et al.
HEMATOLOGICAL ONCOLOGY (2020)
High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients
Irene Prediletto et al.
BONE MARROW TRANSPLANTATION (2019)
High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma
Alexandra Gomez-Arteaga et al.
BONE MARROW TRANSPLANTATION (2019)
Autologous stem cell transfusions on multiple days in patients with multiple myeloma-Does it matter?
Sebastian Moser et al.
HEMATOLOGICAL ONCOLOGY (2019)
Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma
Isabel G. Amsler et al.
LEUKEMIA & LYMPHOMA (2019)
Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myeloma
Ivana Moor et al.
BONE MARROW TRANSPLANTATION (2018)
Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients
Sarah Farag et al.
HEMATOLOGICAL ONCOLOGY (2018)
High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma
D. Sivaraj et al.
BONE MARROW TRANSPLANTATION (2018)
BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients
Stefanie Gilli et al.
ANNALS OF HEMATOLOGY (2017)
Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma
Bernard Maybury et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy
M. Martino et al.
BONE MARROW TRANSPLANTATION (2016)
Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites
Mona Darwish et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Bendamustine in multiple myeloma
Massimo Gentile et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplantation in Multiple Myeloma
Tomer M. Mark et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
An old drug with a new future: bendamustine in multiple myeloma
Massimo Gentile et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
Suzanne Lentzsch et al.
BLOOD (2012)
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
Laura Rosinol et al.
BLOOD (2012)
A Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma
R. Van der Jagt et al.
Current Oncology (2012)
Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study
Antonio Palumbo et al.
BLOOD (2010)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Paul G. Richardson et al.
BLOOD (2010)
Bendamustine: something old, something new
Nishant Tageja et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study
Juan Jose Lahuerta et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
BENDAMUSTINE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
M. Michael et al.
EUROPEAN JOURNAL OF MEDICAL RESEARCH (2010)
BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma
G. Talamo et al.
BONE MARROW TRANSPLANTATION (2009)
Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial
Margarita Blanes et al.
LEUKEMIA & LYMPHOMA (2009)
Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up
Rakesh Popat et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling
Gael Roue et al.
CLINICAL CANCER RESEARCH (2008)
Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents
Lorenzo M. Leoni et al.
CLINICAL CANCER RESEARCH (2008)
Veno-occlusive disease of the liver after high-dose cytoreductive therapy with Busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients
Enric Carreras et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus IV melphalan
J. Vela-Ojeda et al.
ANNALS OF HEMATOLOGY (2007)
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma
M. Wang et al.
HEMATOLOGY (2007)
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone -: a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)
W Pönisch et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2006)
High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study
R Fenk et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma:: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial
P Moreau et al.
BLOOD (2002)
Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma
A Shimoni et al.
BONE MARROW TRANSPLANTATION (2001)
Share Paper
